Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$57.25 - $69.74 $62.6 Million - $76.3 Million
-1,093,510 Reduced 64.0%
615,000 $37 Million
Q3 2023

Nov 14, 2023

BUY
$63.16 - $76.5 $54.3 Million - $65.8 Million
860,410 Added 101.45%
1,708,510 $115 Million
Q2 2023

Aug 14, 2023

BUY
$46.28 - $75.01 $39.3 Million - $63.6 Million
848,100 New
848,100 $58.5 Million
Q3 2022

Nov 14, 2022

SELL
$38.15 - $57.1 $23.7 Million - $35.5 Million
-620,948 Reduced 51.75%
579,052 $23.6 Million
Q2 2022

Aug 15, 2022

BUY
$33.54 - $55.0 $13.1 Million - $21.5 Million
390,000 Added 48.15%
1,200,000 $66 Million
Q1 2022

May 16, 2022

BUY
$31.02 - $48.18 $10.9 Million - $16.9 Million
350,000 Added 76.09%
810,000 $29.4 Million
Q4 2021

Feb 14, 2022

BUY
$41.14 - $56.98 $8.64 Million - $12 Million
210,000 Added 84.0%
460,000 $21.4 Million
Q3 2021

Nov 15, 2021

BUY
$35.31 - $50.56 $8.83 Million - $12.6 Million
250,000 New
250,000 $12.6 Million
Q2 2021

Aug 16, 2021

SELL
$25.8 - $41.09 $33.5 Million - $53.4 Million
-1,300,000 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$23.55 - $32.4 $16.5 Million - $22.7 Million
-700,000 Reduced 35.0%
1,300,000 $37.7 Million
Q4 2020

Feb 16, 2021

BUY
$25.8 - $32.39 $7.04 Million - $8.83 Million
272,733 Added 15.79%
2,000,000 $56.3 Million
Q3 2020

Nov 16, 2020

BUY
$27.5 - $39.61 $19 Million - $27.4 Million
692,095 Added 66.86%
1,727,267 $53.3 Million
Q2 2020

Aug 14, 2020

BUY
$36.1 - $42.56 $37.4 Million - $44.1 Million
1,035,172 New
1,035,172 $44.1 Million

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $6.7B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.